These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19412518)

  • 21. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
    Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
    AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.
    Zhang L; Yu X; Huo L; Lu L; Pan X; Jia N; Fan X; Morana G; Grazioli L; Schneider G
    Eur Radiol; 2019 Oct; 29(10):5205-5216. PubMed ID: 30915560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gadobenate dimeglumine-enhanced liver MRI as the sole preoperative imaging technique: a prospective study of living liver donors.
    An SK; Lee JM; Suh KS; Lee NJ; Kim SH; Kim YJ; Han JK; Choi BI
    AJR Am J Roentgenol; 2006 Nov; 187(5):1223-33. PubMed ID: 17056909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
    Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
    AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.
    Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R
    Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.
    Kim TK; Lee KH; Jang HJ; Haider MA; Jacks LM; Menezes RJ; Park SH; Yazdi L; Sherman M; Khalili K
    Radiology; 2011 Jun; 259(3):730-8. PubMed ID: 21364083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging.
    Runge VM; Kenney CM
    J Magn Reson Imaging; 2000 Jun; 11(6):655-64. PubMed ID: 10862065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection and characterization of focal hepatic lesions: comparative study of MDCT and gadobenate dimeglumine-enhanced MR imaging.
    Lee HY; Lee JM; Kim SH; Shin KS; Lee JY; Han JK; Choi BI
    Clin Imaging; 2008; 32(4):287-95. PubMed ID: 18603184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine.
    Grazioli L; Bondioni MP; Faccioli N; Gambarini S; Tinti R; Schneider G; Kirchin M
    J Gastrointest Cancer; 2010 Dec; 41(4):221-32. PubMed ID: 20405242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
    Lee EJ; Kim DJ; Cho ES; Kim KA
    J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.
    Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R
    Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.
    Scali EP; Walshe T; Tiwari HA; Harris AC; Chang SD
    Can Assoc Radiol J; 2017 Aug; 68(3):293-307. PubMed ID: 28583364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase.
    Jeong WK; Kim YK; Song KD; Choi D; Lim HK
    Clin Mol Hepatol; 2013 Dec; 19(4):360-6. PubMed ID: 24459639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
    Kim JI; Lee JM; Choi JY; Kim YK; Kim SH; Lee JY; Han JK; Choi BI
    Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
    Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
    AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.